Trials / Completed
CompletedNCT04260113
Apatinib for Inoperable Advanced Chondrosarcoma
The Effectivity and Toxicity of Apatinib for Unresectable Advanced Chondrosarcoma: a Multicentric Retrospective Study
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Peking University People's Hospital · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Anti-angiogenesis Tyrosine kinase inhibitors (TKIs) have been proved to show promising effects on prolonging progression-free survival (PFS) for advanced chondrosarcoma after failure of standard multimodal Therapy. Methylsulfonic apatinib is one of those TKIs which specifically inhibits VEGFR-2. This study summarizes the experience of two Peking University affiliated hospitals in off-label use of apatinib in the treatment of extensively pre-treated chondrosarcoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apatinib Mesylate | Apatinib orally 500mg once daily half an hour after meal |
Timeline
- Start date
- 2019-10-01
- Primary completion
- 2020-01-01
- Completion
- 2020-04-01
- First posted
- 2020-02-07
- Last updated
- 2021-01-05
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04260113. Inclusion in this directory is not an endorsement.